Immune drug atezolizumab tested before surgery for rare urinary cancers
NCT ID NCT04624399
First seen Nov 18, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tests whether the drug atezolizumab can shrink tumors in people with certain types of urothelial cancer before they have surgery. About 58 adults will receive two doses of the drug, which helps the immune system attack cancer cells. After treatment, they will have standard surgery to remove the tumor, and researchers will check how well the drug worked and if it is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROGENITAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts and London Hospital NHS Trust
RECRUITINGLondon, United Kingdom
Contact
Contact
Conditions
Explore the condition pages connected to this study.